0 219

Cited 0 times in

Cited 0 times in

Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

DC Field Value Language
dc.date.accessioned2023-06-02T00:43:48Z-
dc.date.available2023-06-02T00:43:48Z-
dc.date.issued2022-09-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194379-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePhase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorE.B. Garon-
dc.contributor.googleauthorS. Lu-
dc.contributor.googleauthorY. Goto-
dc.contributor.googleauthorP.R. De Marchi-
dc.contributor.googleauthorL. Paz-Ares-
dc.contributor.googleauthorD.R. Spigel-
dc.contributor.googleauthorM. Thomas-
dc.contributor.googleauthorJ.C-H. Yang-
dc.contributor.googleauthorA. Ardizzoni-
dc.contributor.googleauthorF. Barlesi-
dc.contributor.googleauthorS. Khanna-
dc.contributor.googleauthorC. Bossen-
dc.contributor.googleauthorM. Carbini-
dc.contributor.googleauthorA. Yovine-
dc.contributor.googleauthorB.C. Cho-
dc.identifier.doi10.1016/j.annonc.2022.08.049-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422039278-
dc.citation.volume33-
dc.citation.number7-
dc.citation.startPageS1414-
dc.citation.endPageS1415-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(7) : S1414-S1415, 2022-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.